Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Germline mutations in a DNA repair pathway are associated with familial colorectal cancer
Pingping Xu, … , Ying-Xuan Chen, Jing-Yuan Fang
Pingping Xu, … , Ying-Xuan Chen, Jing-Yuan Fang
Published September 22, 2021
Citation Information: JCI Insight. 2021;6(18):e148931. https://doi.org/10.1172/jci.insight.148931.
View: Text | PDF
Research Article Gastroenterology Genetics

Germline mutations in a DNA repair pathway are associated with familial colorectal cancer

  • Text
  • PDF
Abstract

Aiming to identify rare high-penetrance mutations in new genes for the underlying predisposition in familial colorectal cancer (CRC), we performed whole-exome sequencing in 24 familial CRCs. Mutations in genes that regulate DNA repair (RMI1, PALB2, FANCI) were identified that were related to the Fanconi anemia DNA repair pathway. In one pedigree, we found a nonsense mutation in CHEK2. CHEK2 played an essential role in cell cycle and DNA damage repair. Somatic mutation analysis in CHEK2 variant carriers showed mutations in TP53, APC, and FBXW7. Loss of heterozygosity was found in carcinoma of CHEK2 variant carrier, and IHC showed loss of Chk2 expression in cancer tissue. We identified a second variant in CHEK2 in 126 sporadic CRCs. A KO cellular model for CHEK2 (CHEK2KO) was generated by CRISPR/Cas9. Functional experiments demonstrated that CHEK2KO cells showed defective cell cycle arrest and apoptosis, as well as reduced p53 phosphorylation, upon DNA damage. We associated germline mutations in genes that regulate the DNA repair pathway with the development of CRC. We identified CHEK2 as a regulator of DNA damage response and perhaps as a gene involved in CRC germline predisposition. These findings link CRC predisposition to the DNA repair pathway, supporting the connection between genome integrity and cancer risk.

Authors

Pingping Xu, Danfeng Sun, Yaqi Gao, Yi Jiang, Ming Zhong, Gang Zhao, Jinxian Chen, Zheng Wang, Qiang Liu, Jie Hong, Haoyan Chen, Ying-Xuan Chen, Jing-Yuan Fang

×

Figure 5

Failure of maintenance of nocodazole-induced G2 arrest and impaired DNA damage–induced apoptosis in CHEK2KO cells.

Options: View larger image (or click on image) Download as PowerPoint
Failure of maintenance of nocodazole-induced G2 arrest and impaired DNA ...
(A) Kinetics of cell cycle progression of CHEK2WT and CHEK2KO cells after nocodazole treatment (2 μM) for 0, 6, and 12 hours. (B) The percentage of cells that arrest at G2 after nocodazole treatment at different time points and concentrations. Data are expressed as mean ± SEM (n = 3). *P < 0.05, nonparametric Mann–Whitney U test. (C) Cellular apoptosis analysis by flow cytometry in CHEK2WT and CHEK2KO cells treated with different concentrations of Adriamycin after 24 hours. (D) The percentage of apoptotic cells calculated by flow cytometry from C. Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, nonparametric Mann–Whitney test. (E) Cell viability detected by a crystal violet assay after cells were treated with different concentrations of nocodazole or Adriamycin. (F) Normalized cell population/well calculated by ImageJ software (NIH) from E. Data are expressed as mean ± SEM (n = 3). *P < 0.05, nonparametric Mann–Whitney U test. (G) Protein levels of pan-p53, phosphorylated p53 (serine 20), and Chk2 in CHEK2WT and CHEK2KO cells after Adriamycin treatment for the indicated times.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts